Turning regulatory readiness into a competitive advantage

For early-stage Biotech, MedTech, and digital health companies, the road from discovery to market is long, expensive, and unforgiving of regulatory missteps. Investors know this, which is why a credible regulatory strategy is often the difference between a startup that raises its next round and one that stalls.

PLG has built a dedicated offering for the specific needs of startups and young innovative companies, distinct from the scale-driven support we provide larger organizations.

 

What we bring

  • A network of domain experts across regulatory affairs, market access, IP, and clinical science, alongside PhDs in biology and chemistry and software engineers, assembled to design comprehensive go-to-market strategies for early-stage companies
  • Status as Privileged Partner for Regulatory & Compliance of EIT Health's Venture Centre of Excellence, connecting startups to funding, expertise, and a European network of academic and industry partners
  • Support navigating regulatory pathways in a way that strengthens your position when engaging VC and corporate investors, helping de-risk your company in their eyes
  • Access to methodologies and validation frameworks built through PLG's academic and institutional partnerships

 

Built for every stage of your journey, from first science to your next raise 

  • Turn science into an investable development & regulatory roadmap — corporate & asset strategy, indication prioritization, business case
  • First-in-human, IND / CTA and early regulator engagement — pre-clinical to Phase III clinical & CMC strategy, CMO selection and oversight
  • Build the early value & market-access story that de-risks the asset — early HTA/P&R thinking and value-dossier groundwork, not bolted on at launch
  • CMC strategy, CMO selection and GxP foundations — the manufacturing and quality backbone regulators and investors both expect to see
  • Fundraising & partnering readiness — equity story, data room, and the regulatory narrative that investors will pressure-test

 

Take one capability area, a few, or all of them — scaled to your stage and therapeutic area.

Why it matters to your fundraising

Investors back companies whose regulatory pathway is credible and well-understood. By building this credibility early, PLG helps position your company as a safer, more attractive bet, whatever stage of funding you are approaching.